Quarterly ResultJul 28, 2026, 04:07 PM
NRC Health Q2 TRCV +11% to $151.9M; Revenue $35.4M; Adj. EPS $0.31
AI Summary
NRC Health announced its second quarter 2026 financial results, reporting an 11% year-over-year increase in Total Recurring Contract Value (TRCV) to $151.9 million and a 4% rise in total revenue to $35.4 million. The company posted a GAAP net loss of ($3.3) million, or ($0.15) per diluted share, but achieved an Adjusted Net Income of $6.9 million, or $0.31 per diluted share. Additionally, the Board of Directors declared a quarterly cash dividend of $0.16 per share.
Key Highlights
- Total Recurring Contract Value (TRCV) increased 11% year-over-year to $151.9 million.
- Total revenue for Q2 2026 was $35.4 million, up 4% from the prior year.
- GAAP net loss was ($3.3) million, or ($0.15) per diluted share.
- Adjusted Net Income was $6.9 million, or $0.31 per diluted share.
- Adjusted EBITDA was $9.4 million, representing 27% of revenue.
- Net cash flow from operating activities was $1.4 million.
- Free cash flow was $0.1 million.
- Quarterly cash dividend of $0.16 per share declared, payable October 9, 2026.
Price Impact
More from NRC